Apr 24, 2025, 19:40

Harold E. Johns Studentship Program

The Harold E. Johns Studentship Program aims to inspire undergraduate students in physics or related disciplines to pursue careers in medical physics in oncology within the Ontario cancer care system. Named after the pioneering Canadian physicist Dr. Harold E. Johns, this 4-month research experience provides mentorship and hands-on project work at one of Ontario’s Regional Cancer Centres.

Eligibility Criteria

Undergraduate students returning to study in a related program, OR Recent graduates enrolled or applying to a graduate physics/biophysics program

Must have a minimum GPA of 3.30
Must not have held this studentship previously
Must demonstrate a clear interest in medical physics

Participating Cancer Centres (One studentship per site)

Princess Margaret Cancer Centre (Toronto)
Odette Cancer Centre (Toronto)
Juravinski Cancer Centre (Hamilton)
London Regional Cancer Program (London)
The Ottawa Hospital Regional Cancer Centre (Ottawa)
And 10 other regional centres across Ontario

Funding Details

Stipend administered through the host cancer centre
Funding is provided by Ontario Health (Cancer Care Ontario)
Students work closely with a supervisor on a defined project
Required to submit a final report (~5 pages) in an approved format

Key Details

Duration: ~4 months
Location: Ontario, Canada (at 1 of 15 Regional Cancer Programs)
Number of Awards: Up to 15 annually
Application: Transcript, CV, and a motivation letter sent to local program directors
Deadline: Varies by centre – contact the local director for exact dates

Further Information

For more information on application procedures, eligibility confirmation, or centre-specific deadlines, contact the local program director at chosen Regional Cancer Centre.

Canadian cancer research cancer Cancer Care Ontario Harold E. Johns Harold E. Johns Studentship medical physics OncoDaily Oncology oncology careers Ontario Health physics studentship radiation oncology regional cancer programs undergraduate research

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

Happy Birthday OncoDaily!

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer